These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38681395)

  • 21. Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases.
    Jha A; Misra A; Gupta R; Ghosh A; Tyagi K; Dutta K; Arora B; Durani S
    Diabetes Metab Syndr; 2020; 14(3):213-216. PubMed ID: 32172176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients.
    Shalmon D; Bar-Ilan E; Peled A; Geller S; Bar J; Schwartz N; Sprecher E; Pavlovsky M
    Acta Derm Venereol; 2024 Apr; 104():adv26663. PubMed ID: 38576104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
    Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
    JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bullous Pemphigoid Associated With Dipeptidyl Peptidase-4 Inhibitors: A Case Report and Review of Current Evidence.
    Hadjkacem F; Frikha H; Boujelben K; Chaari C; Mnif E; Masmoudi A; Boudawara T; Turki H; Abid M
    Hosp Pharm; 2023 Aug; 58(4):357-362. PubMed ID: 37360199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases.
    Yoshiji S; Murakami T; Harashima SI; Ko R; Kashima R; Yabe D; Ogura M; Doi K; Inagaki N
    J Diabetes Investig; 2018 Mar; 9(2):445-447. PubMed ID: 28520234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors].
    Kodera R; Chiba Y; Tamura Y; Miyazawa R; Tanei R; Mori S; Ito H; Araki A
    Nihon Ronen Igakkai Zasshi; 2019; 56(1):43-50. PubMed ID: 30760682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    Bellinato F; Maurelli M; Schena D; Gisondi P; Girolomoni G
    Ital J Dermatol Venerol; 2021 Aug; 156(4):455-459. PubMed ID: 32545941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
    Jedlowski PM; Jedlowski MF; Fazel MT
    Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.
    Yu-Yang S; Chu-Sung Hu S; Yiao-Lin S
    Acta Dermatovenerol Croat; 2017 Oct; 25(3):255-256. PubMed ID: 29252183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.
    Silverii GA; Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
    Endocrine; 2020 Sep; 69(3):504-507. PubMed ID: 32236820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
    Phan K; Charlton O; Smith SD
    Australas J Dermatol; 2020 Feb; 61(1):e15-e21. PubMed ID: 31215644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    Muramatsu K; Zheng M; Yoshimoto N; Ito T; Ujiie I; Iwata H; Shimizu H; Ujiie H
    J Dermatol Sci; 2020 Oct; 100(1):23-30. PubMed ID: 32843228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database.
    García M; Aranburu MA; Palacios-Zabalza I; Lertxundi U; Aguirre C
    J Clin Pharm Ther; 2016 Jun; 41(3):368-370. PubMed ID: 27191539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
    Sawada K; Sawada T; Kobayashi T; Fujiki A; Matsushita T; Kawara S; Izumi K; Nishie W; Shimizu H; Takehara K; Hamaguchi Y
    Immunol Med; 2021 Mar; 44(1):53-55. PubMed ID: 32634333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients.
    Balighi K; Heidari S; Kavyani M; Kamyab Hesari K; Tootoonchi N
    Case Rep Dermatol; 2022; 14(3):350-355. PubMed ID: 36466751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin.
    Mendonça FM; Martín-Gutierrez FJ; Ríos-Martín JJ; Camacho-Martinez F
    Dermatology; 2016; 232(2):249-53. PubMed ID: 26820308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
    Reolid A; Muñoz-Aceituno E; Rodríguez-Jiménez P; González-Rojano E; Llamas-Velasco M; Fraga J; Daudén E
    Int J Dermatol; 2020 Feb; 59(2):197-206. PubMed ID: 31605541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication.
    Shinohara Y; Iijima T; Sakurai S; Jojima T; Ohira E; Hayashi S; Usui I; Igawa K; Aso Y
    Clin Case Rep; 2020 Oct; 8(10):2007-2012. PubMed ID: 33088540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
    Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
    Front Immunol; 2018; 9():542. PubMed ID: 29706950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.